Condition: Healthy Participants · Schizophrenia Diagnosis · Sponsor: Neurosterix
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
This description comes directly from the study's public registry record.
Doug Feltner, Chief Medical Officer, MD · +41 22 884 15 55 · doug.feltner@neurosterix.com
Lisa Corey · +41 22 884 15 55 · lisa.corey@neurosterix.com
Always discuss trial participation with your own doctor first.
| Collaborative Neuroscience Research, LLC - CenExel | Los Alamitos, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07344948